

**Contacts Media**

Amsterdam +31 20 721 4133  
Dublin +39 02 72 42 62 13  
Milan +39 02 72 42 67 56  
Paris +33 1 70 48 24 45


Brussels +31 20 721 4133  
Lisbon +351 91 777 68 97  
Oslo +47 41 69 59 10

**Contact Investor Relations**

+33 1 70 48 24 17

## ONWARD Medical lists on Euronext Paris

- **Market capitalisation of €175.914 million**



**Paris – 24 September 2024** – Euronext today congratulates ONWARD Medical on its additional listing on Euronext Paris (ticker code: ONWD). ONWARD Medical is also listed on Euronext Brussels and Euronext Amsterdam.

ONWARD Medical is a technology company creating innovative spinal cord stimulation therapies<sup>1</sup> to restore movement, function, and independence in people with spinal cord injury (SCI). The company closely works with CEA-Climattec, a world renowned biomedical research institute based in Grenoble (France), funded by the French government. The two companies are leading clinical research by combining the investigational WIMAGINE® BCI interface from CEA-Clinattec with the investigational ONWARD ARC-IM® System (an implanted technology that delivers targeted stimulation to the spinal cord) to create a DigitalBridge™ across the injured spinal cord. This investigational system is named ARC-BCI™.

On 19 September 2024, the company announced that the most recent participant to its study had been implanted with the ARC-BCI System to restore lower limb mobility after spinal cord injury. The implant procedure was performed on September 12, 2024, by Jocelyne Bloch, MD, head of functional neurosurgery at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland.

The market capitalisation of ONWARD Medical is made of 34 628 832 ordinary shares. At market close on 23 September 2024, the share price of the company was at €5.08 per share. ONWARD Medical market capitalisation at market close on 23 September 2024 was of €175.914 million.

**Dave Marver, CEO of ONWARD Medical**, said: "We are extremely proud to be facilitating trading of ONWARD Medical shares by making them available on Euronext Paris. Our company benefits from a special link with France, highlighted by our crucial collaboration on brain-computer interface research with CEA-Clinattec. This listing provides greater access to French investors, thereby supporting our efforts to address the significant unmet needs of people suffering from spinal cord injuries in France and around the world."

<sup>1</sup> All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.



**Caption:** Dave Marver, CEO of ONWARD Medical, rang the bell this morning in the presence of his teams and of Alain Baetens, Corporate Sales Director to celebrate the listing on Euronext Paris of ONWARD Medical.

#### CONTACT EURONEXT

Flavio Bornancin-Tomasella  
(Corporate, Paris)

+33 1 70 48 24 45

[parispressoffice@euronext.com](mailto:parispressoffice@euronext.com)

#### CONTACTS ONWARD MEDICAL

##### For Media Inquiries

Aditi Roy, VP Communications

[media@onwd.com](mailto:media@onwd.com)

##### For Investor Inquiries

Amori Fraser, Finance Director

[investors@onwd.com](mailto:investors@onwd.com)

##### For Public Relations in France

Gabriel Rafaty, Aimpact

[gr@aimpact.net](mailto:gr@aimpact.net)

#### About ONWARD Medical

ONWARD® Medical is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of scientific discovery, preclinical, and clinical research conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy™, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA).

ONWARD ARC Therapy is targeted, programmed spinal cord stimulation designed to be delivered by the Company's external ARC-EX® or implantable ARC-IM® platforms. ARC Therapy can also be delivered by the Company's ARC-BCI™ platform, which pairs the ARC-IM System with brain-computer interface (BCI) technology to restore movement after SCI with thought-driven control.

Use of non-invasive ARC-EX Therapy significantly improved upper limb function after SCI in the global pivotal Up-LIFT trial, with results published by Nature Medicine in May 2024. The Company has submitted its regulatory application to the FDA for clearance of the ARC-EX System in the US and is preparing for regulatory submission in



Europe. In parallel, the Company is conducting clinical studies with its ARC-IM Therapy, which demonstrated positive interim clinical outcomes for improved blood pressure regulation following SCI. Other ongoing clinical studies focus on using ARC-IM Therapy to address mobility after SCI and gait challenges in Parkinson's disease as well as using the ARC-BCI platform to restore thoughtdriven movement of both upper and lower limbs after SCI.

Headquartered in Eindhoven, the Netherlands, ONWARD Medical has a Science and Engineering Center in Lausanne, Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Brussels and Amsterdam (ticker: ONWD).

For more information, visit <https://www.onwd.com/>, and connect with us on [LinkedIn](#) and [YouTube](#).

## About Euronext

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end of June 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe's leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. For the latest news, go to [euronext.com](https://euronext.com) or follow us on X ([twitter.com/euronext](https://twitter.com/euronext)) and LinkedIn ([linkedin.com/company/euronext](https://linkedin.com/company/euronext))

## Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at [www.euronext.com/terms-use](https://www.euronext.com/terms-use).

© 2024, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: [www.euronext.com/privacy-policy](https://www.euronext.com/privacy-policy). In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: [www.euronext.com/data\\_subjects\\_rights\\_request\\_information](https://www.euronext.com/data_subjects_rights_request_information). To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at [connect2.euronext.com/form/data-subjects-rights-request](https://connect2.euronext.com/form/data-subjects-rights-request) or email our Data Protection Officer at [dpo@euronext.com](mailto:dpo@euronext.com).

